Two leaders at Brainstorm Cell Therapeutics, which is developing the experimental cell-based therapy NurOwn (debamestrocel) for people with amyotrophic lateral sclerosis (ALS), have published a paper calling on the U.S. Food and Drug Administration (FDA) to modernize its review process for experimental therapies for ALS and other…
News
Several nonprofits are uniting to fund new research aimed at identifying targets for the treatment of amyotrophic lateral sclerosis (ALS). The new initiative will be led by the Allen Institute, a nonprofit medical research organization, through its Brain Health Accelerator — a research initiative to study neurodegenerative diseases. The…
PAS-004, an experimental therapy that Pasithea Therapeutics is developing to address inflammation and TDP-43 protein clumps, has received orphan drug designation by the U.S. Food and Drug Administration for the treatment of amyotrophic lateral sclerosis (ALS). The status aims to accelerate the development of therapies for rare diseases, or…
An arm of the HEALEY ALS platform trial testing Neurizon Therapeutics’ experimental therapy NUZ-001 as a treatment for amyotrophic lateral sclerosis (ALS) is expanding enrollment from 160 to as many as 240 participants. The decision follows enrollment that exceeded original expectations and the absence of another HEALEY regimen…
Regulatory authorities in the Netherlands have given the green light for a clinical trial testing Ability Neurotech‘s experimental brain-implantable technology as a way to restore communication and speech in people with amyotrophic lateral sclerosis (ALS). The study is designed to assess whether the system can support independent communication…
Tomorrow, June 2, is Lou Gehrig Day, an annual event that honors the life and legacy of Lou Gehrig, the record-setting baseball player who died from amyotrophic lateral sclerosis (ALS) more than 80 years ago. Major League Baseball (MLB) designated June 2 to honor Gehrig because it marks when…
French actor Pierre Deny, known for his role in the Netflix streaming series “Emily in Paris,” has died from amyotrophic lateral sclerosis (ALS) at age 69. “It is with deep emotion that we announce the passing of Pierre Deny, which occurred this Monday following a sudden and severe case of…
Living in areas with a moderate amount of green space appears to reduce the likelihood of developing amyotrophic lateral sclerosis (ALS) — but both very low and very high levels of greenness may increase the odds for different reasons, according to a study from Italy. The findings “may have…
There is an association between traumatic head injuries and amyotrophic lateral sclerosis (ALS), but the nature of this relationship remains unclear, according to a review and meta-analysis of published studies. People who had a history of a traumatic head injury were nearly 50% more likely than those without head…
AC Immune’s experimental imaging agent ACI-19626 continues to show a good safety profile and has shown promise for detecting toxic TDP-43 protein clumps in people with amyotrophic lateral sclerosis (ALS). That’s according to new data from an ongoing Phase 1 clinical trial (NCT06891716), in which the PET…
Recent Posts
- Brainstorm leaders urge FDA to update treatment review process
- New ALS research effort aims to speed search for treatments
- The conclusions I reach when I imagine life without ALS
- FDA grants orphan status to new ALS drug candidate PAS-004
- Living simply with ALS means taking it one absurdity at a time